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Abstract
Background and Objective: Acne in women can often be
successfully treated by the intake of oral contraceptives
containing gestagens with anti-androgenic properties.
This study aimed to evaluate the efficacy of the mono-
phasic oral contraceptive ethinylestradiol/chlormadi-
none acetate (EE/CMA; Belara®) for the treatment of mild
to moderate papulopustular acne of the face and acne-
related disorders in comparison to EE/levonorgestrel
(LNG; Microgynon®). Methods: 199 female acne patients
were enrolled in a single-blind, randomized, multicentre
phase III study and divided into two groups who received
either EE/CMA or EE/LNG. The primary end point was ful-
filled if the number of papules/pustules per half of the
face present on admission had decreased by at least 50%
in the 12th medication cycle. Results: 59.4% of the wom-
en under EE/CMA and 45.9% under EE/LNG were re-
sponders. The relative frequency of women with com-
plete resolution was 16.5% under EE/CMA and 4.3%
under EE/LNG at cycle 12. Conclusion: EE/CMA is an effi-
cient treatment for women with mild and moderate
papulopustular acne of the face and related disorders,
reflecting the well-known anti-androgenic properties of
the progestogen CMA.
Copyright © 2001 S. Karger AG, Basel
Introduction
Acne is a common skin disorder characterized by an
overproduction of sebum leading to non-inflammatory
(comedones) and inflammatory lesions (papules, pustules,
nodulocystic lesions). Its aetiology is multifactorial. Most
women with acne may suffer from a hypersensitivity of
the sebaceous glands to androgens, but frequently an
excess of androgens can also be observed. In the sebaceous
gland the enzyme 5·-reductase type I converts testoster-
one to its more active component dihydrotestosterone
which in turn stimulates the activity of the sebaceous
glands. As hormonal balance is a key factor in the aetiolo-
gy of acne, one possible treatment is systemic hormonal
therapy. The use of oral contraceptives with anti-andro-
genic properties has proven to be a useful approach
towards this goal [1, 2].
Belara® (ethinylestradiol/chlormadinone acetate, EE/
CMA) is a monophasic oral contraceptive containing 0.03
mg EE and 2 mg CMA which was registered in Germany
in 1998. Oestrogens are known to suppress pituitary
gonadotropin secretion, thereby inhibiting androgen bio-
synthesis in ovaries and adrenals [3–5]. Additionally, they
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may have a direct effect on sebum production [6] and raise
the sex-hormone-binding globulin (SHBG) levels [7],
which in turn lowers circulating testosterone. CMA is a
progestogen derivative with anti-androgenic properties. It
reduces clinical manifestations of acne by competing with
endogenous androgens at their receptors in the sebaceous
gland cells and by inhibiting 5·-reductase type I [8, 9].
The present phase III study compared the efficacy and
safety of the combination pill EE/CMA for the treatment
of acne of the face, décolleté (i.e. chest) and back, of
seborrhoea, alopecia and hirsutism with another com-
monly used oral contraceptive combining 0.03 mg EE and
0.15 mg levonorgestrel (EE/LNG; Microgynon®).
Methods
This study was designed as a single-blind (investigator), random-
ized (1:1), controlled, parallel, multicentric phase III trial. It was per-
formed at 32 office-based gynaecological centres in Germany. The
participating gynaecologists were instructed and trained in identi-
fying and differentiating as well as in the counting of papules, pus-
tules or comedones according to the definition of Cook et al. [10] and
underwent a self-training phase (i.e. interassessment training) prior
to the first recruitment of patients to assure consistency and repro-
ducibility in the evaluation of acne lesions. The study was conducted
according to the principles of Good Clinical Practice as specified in
the Guidelines of the European Community. The study protocol was
approved by the local ethics committees.
Women of reproductive age with mild to moderate papulopustu-
lar acne of the face aged between 18 and 40 years (smokers up to 30
years) were randomly allocated to EE/CMA or EE/LNG. Both study
medications were to be taken over 12 treatment cycles. After check-
ing inclusion and exclusion criteria, explanation of the study and
obtaining written informed consent both ‘pill starters’ (first intake of
an oral contraceptive or no intake of an oral contraceptive during the
last 3 months prior to admission) and ‘pill switchers’ (change of a
previous oral contraceptive to study medication with a break of less
than 3 months in-between) received one package of study medication
containing 3 blisters with 21 film-coated tablets/dragees of EE/CMA
or EE/LNG for the first 3 cycles. Patients were not allowed to take
hormonal contraception as well as topical or systemic acne therapy
during the study. Systemic acne therapy (e.g. with anti-androgens or
retinoids) during the last 6 months prior to study start was also
excluded.
The first pill of the study medication was to be taken on the first
day of withdrawal bleeding in the first medication cycle and thereaf-
ter for 21 days, every day at the same time, preferably in the evening.
This phase was followed by a 7-day pill-free interval during which
withdrawal bleeding usually occurred. All subsequent cycles began
on the same day of the week as the first day of the first cycle, irrespec-
tive of whether withdrawal bleeding had occurred or was still present.
Each participant received a cycle calendar, where the beginning of
study medication, all adverse events, missed pills, bleeding events
and concomitant medication, if taken, had to be documented; these
entries were transferred into the case report form. General medical,
dermatological and gynaecological examinations including Pap
smears and pregnancy tests were performed on admission and at reg-
ular intervals during the study course. In addition, blood samples
were collected on admission and between the 1st and 8th days of
cycles 2, 4, 7, 10 and 12 for safety screening and for determination of
hormone parameters [testosterone, free testosterone, dehydroepian-
drosterone sulphate (DHEA-S), SHBG, luteinizing hormone, follicle-
stimulating hormone, androstenedione, 17-·-OH-progesterone].
Regular dermatological examinations were performed in cycles 4,
7, 10 and 12; these included counting of acne lesions and the assess-
ment of seborrhoea, alopecia and hirsutism. A modified Plewig score
[11] assessing the number of inflammatory lesions was used to classi-
fy the degree of severity of facial acne at baseline and during the
study: acne of grade 0 was defined as consisting of up to 3 papules/
pustules per half of the face, grade I acne of 4–10, grade II of 11–20,
grade III of 21–30 and grade IV of more than 30 papules/pustules per
half of the face. The primary study end point was defined as a
decrease by at least 50% in papules/pustules per half of the face in the
12th treatment cycle compared to the number of lesions at admis-
sion. If the acne was asymmetric, the more affected half of the face
was to be taken at each respective visit. A lesion on the midline of the
face was counted to the more affected half of the face. The evaluation
of the response rates was performed by a Cochran-Mantel-Haenszel
test (CMH test). Drop-outs were defined as non-responders in the
intention-to-treat population for the primary end point. Secondary
end points were the assessment of comedonal acne of the face, acne of
the décolleté and back (number of comedones and papules/pustules),
further signs of androgenization such as seborrhoea, alopecia and hir-
sutism (according to an intensity scale: mild, moderate, severe; for
hirsutism the localization was given, data not shown) as well as blood
levels of androgens and SHBG, cycle stability and incidence of
adverse events.
Results
Participants
In this study 32 gynaecologists in Germany recruited
199 patients. One hundred and one volunteers were ran-
domly allocated to EE/CMA and 98 to EE/LNG. Both
treatment groups were comparable to each other concern-
ing demographic data (age, weight, height, Broca index,
body mass index), alcohol consumption, smoking habits
(47/199 smokers), gynaecological and bleeding history
and concomitant diseases. On admission, all patients in
both study groups suffered from papulopustular acne of
the face; most of the patients were assigned to Plewig
grades I and II [11]; 55.4% (56/101) in the EE/CMA and
52% (51/98) in the EE/LNG group had acne of the décol-
leté, and 52.5% (53/101) in the EE/CMA and 48% (47/98)
in the EE/LNG group had acne of the back (all Plewig
grade I or II, except 1 patient with grade IV in the EE/
LNG group). The number of patients of each study group
assigned to each classification was comparable. One
hundred and fifty patients (78 on EE/CMA, 72 on EE/
LNG) completed all 12 medication cycles, and 148 pa-
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tients (78 on EE/CMA and 70 on EE/LNG) finished the
study according to protocol. Twenty-three patients on EE/
CMA and 26 on EE/LNG terminated the study prema-
turely, mainly due to adverse events, lack of efficacy of
study medication, protocol deviations, non-compliance,
wish to conceive and pregnancy.
Effect of Study Medication on Papulopustular Acne of
the Face
In total, 60 of the 101 patients (59.4%) on EE/CMA
and 45 of the 98 patients (45.9%) on EE/LNG were
responders according to the definition of the primary end
point (i.e. they showed a reduction of papules/pustules of
at least 50% in the 12th treatment cycle). This superiority
of EE/CMA over EE/LNG was statistically significant
(CMH test, p = 0.02).
At admission, both medication groups started with a
median number of 8.0 papules/pustules (Q1–Q3 interval:
6–13) per half of the face. A gradual reduction of these
numbers from admission until cycle 12 was observable for
both medication groups (fig. 1a). Accordingly, the num-
ber of women with complete resolution (i.e. no papules/
pustules) increased continuously under EE/CMA reach-
ing a relative number of 10.1% (9/89 patients) by cycle 7
and of 16.5% (13/79 patients) by cycle 12. In comparison,
in the EE/LNG group only 5% (4/80) of the patients were
cured by cycle 7 and 4.3% by cycle 12, respectively. These
results point to an earlier onset and a more pronounced
improvement of papulopustular acne of the face under
EE/CMA. In 98.7% (78 of 79 patients) of the EE/CMA
patients and 87.1% (61 of 70 patients) of the EE/LNG
patients an improvement of their facial acne was reported
after cycle 12. A deterioration (i.e. an increase in the num-
ber of pustules/papules) was seen in 11.4% (8 of 70
patients) of the EE/LNG group whereas in the EE/CMA
group no exacerbation was observable in the 12th treat-
ment cycle.
Summarizing the results in other words, in cycle 12,
67.1% (53 of 79) of the patients under EE/CMA and
54.3% (38 of 70) of the women of the EE/LNG group
could be assigned to Plewig score 0, and 7.6% (6 of 79)
under EE/CMA and 17.1% (12 of 70) under EE/LNG still
had grade II acne according to Plewig.
In order to investigate whether the previous intake of
an oral contraceptive could have an influence on the
response rate, a stratification analysis was performed (i.e.
pill switcher and pill starter in each treatment group).
There were 41.6% (42/101) pill switchers in the EE/CMA
group and 40.8% (40/98) in the EE/LNG group, respec-
tively. Response rates for switchers and starters per treat-
Fig. 1. a Median numbers of papules/pustules of the face in women
treated with Belara (EE/CMA) and Microgynon (EE/LNG) from
cycle 0 (admission) until cycle 12 (end of study). b Median numbers
of comedones of the face in women treated with Belara (EE/CMA)
and Microgynon (EE/LNG) from cycle 0 (admission) until cycle 12
(end of study).
ment group are given in table 1. For both subgroups, again
a superiority of EE/CMA was shown, being especially pro-
nounced among pill switchers. This has also been proven
statistically by including starters and switchers as an addi-
tional stratification variable in the statistical test (CMH
test, p = 0.014).
Effect of Study Medication on Comedonal Acne of the
Face
Similar trends could be detected for comedonal acne of
the face. In each medication group, 88 patients presented
with comedones at admission. Throughout the study
there was a gradual reduction in numbers of comedones
from admission to cycle 12 which was greater with EE/
CMA than with EE/LNG (fig. 1b). With EE/CMA, an
improvement rate of 70.1% (61/87 patients) was already
Pill starters
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Fig. 2. Improvement, healing and deteriora-
tion rates for papulopustular acne of the
face, décolleté and back under Belara (EE/
CMA) and Microgynon (EE/LNG) after 12
treatment cycles.
Table 1. Absolute and relative numbers
of non-responders and responders among
pill starters and pill switchers in each
study group
Study subgroup Study group Non-responders Responders Total
EE/CMA
EE/LNG
22 (37.3)
26 (44.8)
37 (62.7)
32 (55.2)
59 (100)
58 (100)
Pill switchers EE/CMA
EE/LNG
19 (45.2)
27 (67.5)
23 (54.8)
13 (32.5)
42 (100)
40 (100)
Total EE/CMA
EE/LNG
41 (40.6)
53 (54.1)
60 (59.4)
45 (45.9)
101 (100)
98 (100)
Figures in parentheses indicate percentages.
seen in cycle 4 compared to 56.5% (48/85 patients) in the
EE/LNG group, and by cycle 12, 88.9% (64/72) of the
patients with facial comedones under EE/CMA and only
77.3% (51/66) under EE/LNG showed improvement of
their lesions. Furthermore, deterioration rates of come-
donal acne of the face were much lower in the EE/CMA
(2.8%) than in the EE/LNG group (9.1%) at the 12th
treatment cycle.
Effect on Acne of the Décolleté after 12 Treatment
Cycles
On admission, 55.4% (56/101) of the patients on EE/
CMA and 52% (51/98) patients on EE/LNG suffered
from papulopustular or comedonal acne of the décolleté.
Whereas 45.7% of the patients (21/46) under EE/CMA
were completely cured by cycle 12, this was the case for
only 21.6% (8/37) patients under EE/LNG. The improve-
ment rate for either papulopustular or comedonal acne of
the décolleté was 95.6% (43/45) and 91.9% (34/37) under
EE/CMA compared to 81.1% (30/37) and 73.1% (19/26)
under EE/LNG. Only 1 woman (2.7%) under EE/CMA
had an exacerbation of her comedonal acne on the décol-
leté reported in cycle 12, but deterioration occurred under
EE/LNG in 13.5% of patients with papulopustular acne
(fig. 2) and in 15.4% with comedonal acne at cycle 12.
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Fig. 3. a Median SHBG levels (nmol/l) at baseline, stratified and not
stratified into pill switchers and pill starters for both study groups.
b SHBG levels during the course of the study in the two medication
groups.
Effect on Acne of the Back after 12 Treatment Cycles
On admission, 52.5% (53/101) of the patients in the
EE/CMA and 48% (47/98) in the EE/LNG groups re-
ported acne of the back. Of these patients, 41.9% (18/
43) on EE/CMA and 17.6% (6/34) on EE/LNG were
cured by cycle 12. Papulopustular acne as well as come-
donal acne of the back improved in almost 100% of
patients under EE/CMA (97.7%, i.e. 42/43, and 97.3%,
i.e. 36/37, respectively) and in a smaller number of
patients under EE/LNG (87.9%, i.e. 29/33, and 76.9%,
i.e. 20/26, respectively) by the end of the study. No dete-
rioration of acne lesions on the back was reported under
EE/CMA in cycle 12, whereas under EE/LNG papulo-
pustular acne deteriorated in 6.1% (n = 2/33) and come-
donal acne in 11.5% (n = 3/26) of the patients at that
time point. Figure 2 summarizes the relative frequencies
of patients showing effects of both kinds of study medica-
tion on acne of the face, décolleté and back after 12 treat-
ment cycles.
Effect on Seborrhoea, Alopecia and Hirsutism after 
12 Treatment Cycles
At baseline, 31.7% (32/101) of the women under EE/
CMA and 30.6% (30/98) under EE/LNG suffered from
seborrhoea mostly of mild (75% in EE/CMA vs. 60% in
EE/LNG) or moderate (15.6% in EE/CMA vs. 30% in EE/
LNG) intensity. In both medication groups there was a
decrease in the number of patients with seborrhoea after
12 treatment cycles: 80% (20/25) of the volunteers in the
EE/CMA group showed total resolution versus 76.2% (16/
21) in the EE/LNG group.
Similar results were observed among the patients with
androgen-dependent alopecia. Resolution rates of 85.7%
(6 of 7 patients) in the EE/CMA group and 90.9% (10 of
11 patients) with EE/LNG were achieved. Due to the
small number of patients the results give only a hint that
the treatments are effective.
Hirsutism, irrespective of the localization, was present
in 13.9% of patients under EE/CMA (i.e. 14 women) and
in 20.4% (20 patients) under EE/LNG at baseline. It dis-
appeared completely in about one third of patients in each
medication group after 12 cycles of treatment: 36.4% of
patients on EE/CMA (4/11 women) versus 35.7% on EE/
LNG (5/14 women). Again, due to the small patient popu-
lation these data give only a trend.
Sex Hormones and SHBG
At baseline, median SHBG levels were already posi-
tioned at the upper end of the reference range (16–120
nmol/l, fig. 3a). This was probably due to the fact that
both study groups contained pill switchers with already
elevated SHBG levels at admission. This assumption was
confirmed by a stratification analysis of pill switchers and
starters concerning baseline SHBG values (fig. 3a).
During the study there was an increase of almost dou-
ble in the SHBG plasma values under EE/CMA. This
increase was already present in cycle 4. In contrast, un-
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der EE/LNG, SHBG plasma levels decreased slightly
(fig. 3b).
No major changes in androgen levels during treatment
were seen.
Tolerability
Both drugs were well tolerated as reflected by the low
incidence and intensity of adverse events.
In total, 103 out of 199 patients (51.8%) reported
adverse events, most frequently in the first 3–4 cycles for
both medication groups. Under EE/CMA, a total of 421
adverse events in 53 patients compared to 568 adverse
events in 50 patients under EE/LNG were reported. The
most frequently observed adverse events were headache
(24/97, 24.7%), breast tension (19/97, 19.6%), dysmen-
orrhoea (10/97, 10.3%) and nausea (10/97, 10.3%) for the
EE/CMA study group and headache (29/94, 30.9%), nau-
sea (16/94, 17%), dysmenorrhoea (15/94, 16%) and breast
tension (14/94, 14.9%) for EE/LNG. These are common
adverse events of oral contraceptives.
Most adverse events were classified as mild or moder-
ate (72.4% for EE/CMA vs. 64.3% for EE/LNG).
The majority of patients in both medication groups
had regular withdrawal bleedings with onset within the
medication-free interval lasting 4–5 days.
There was no major difference in incidence and inten-
sity of intracyclic bleeding between the medication
groups. Amenorrhoea occurred in only 1.5% of cycles
under EE/CMA and in 1.8% of cycles under EE/LNG.
Discussion
As acne is mainly characterized by the overproduction
of sebum in response to the stimulation of the sebaceous
glands by androgens, it can often be successfully im-
proved by the intake of oral contraceptives with anti-
androgenic properties [1]. The present study was focused
on the comparison of the effects of two low-dose oestro-
gen-progestogen combinations, EE/CMA (Belara) and
EE/LNG (Microgynon), on mild to moderate papulopus-
tular acne of the face.
Efficacy on Acne of the Face, Décolleté and Back
EE/CMA was superior to EE/LNG (p = 0.02, CMH
test) in reducing the clinical symptoms papules/pustules
of facial acne. After 12 treatment cycles, response rates of
59.4% under EE/CMA and 45.9% under EE/LNG were
reached. This difference between the two study medica-
tions was even more pronounced for acne of the décolleté
and the back. For both localizations, an earlier improve-
ment and fewer cases with exacerbation under EE/CMA
were observed.
Sansone and Reisner [12] noted that the majority of
women suffering from acne show a 2- to 3-fold elevated
activity of 5-·-reductase type I, the enzyme that converts
testosterone into its active component dihydrotestoster-
one which stimulates the sebaceous glands. The CMA pre-
sented in Belara is a competitive inhibitor of the androgen
receptor (e.g. of the sebaceous gland cells). Several publi-
cations have also documented positive effects of anti-
androgens, such as CMA and cyproterone acetate (CPA)
on clinical manifestations of acne, seborrhoea, alopecia
and hirsutism [1, 8, 9, 13]. Kaiser [1] using a CMA-con-
taining biphasic oral contraceptive observed resolution
rates of 14.5% in patients with facial papulopustular acne
after 12 treatment cycles. Similar resolution rates (16.5%)
were seen in the present study.
The effects of the CMA in Belara on clinical signs of
acne and related disorders are additionally enhanced by
the oestrogen component of the pill, EE. EE raises the lev-
els of SHBG leading to a lower level of circulating testos-
terone. Other ‘anti-androgenic’ effects of EE, which were
proven in animal models, are the inhibition of 5-·-reduc-
tase type I [14, 15] as well as a direct effect on sebum pro-
duction [6]. Finally, both CMA and EE suppress the secre-
tion of gonadotropins of the pituitary gland. This leads to
an associated reduction in androgen secretion of the ovary
and adrenal cortex. The marked treatment success in
women on EE/CMA which occurred already in the 4th
treatment cycle exceeded the effect seen with Microgynon
by far. This indicates that the anti-androgenic activity of
CMA adds to the oestrogen effect of EE, thus underlining
that the combination of both components seems to be
responsible for the considerably better total treatment
success of Belara in acne and other androgen-related
symptoms. These results are further supported by the
results of a comparative study where an LNG-containing
contraceptive (Neovletta® with 0.03 mg EE and 0.15 mg
LNG, which is identical with the contents of Microgynon)
was compared to two hormonal combinations containing
2 mg CPA and different amounts of EE (Dianette® and
Diane®, 35 and 50 Ìg, respectively) for the treatment of
acne over 6 cycles [2]. After 4 cycles under CPA, the
patients had a significantly higher reduction in the num-
ber of acne lesions compared to those on EE/LNG. Wom-
en taking EE/LNG showed an average reduction of acne
lesions by 35%; this is of the same order of magnitude as
determined for patients on placebo by Lucky et al. [7] and
Redmond et al. [5]. In contrast, in women who took an
44 Dermatology 2001;203:38–44 Worret/Arp/Zahradnik/Andreas/Binder
anti-androgenic oral contraceptive (EE/CPA) the average
reduction of acne lesions reached 70%, again confirming
the assumed superiority of anti-androgenic oral contra-
ceptives for the treatment of this skin disorder.
SHBG and Androgen Levels
There was no noteworthy change in the levels of testos-
terone, free testosterone, dihydrotestosterone or DHEA-S
under EE/CMA and EE/LNG. The SHBG levels rose
strikingly under EE/CMA to almost double the baseline
values as early as after 4 treatment cycles. This points to
the oestrogenic influence not being counteracted by
CMA. In the EE/LNG group, SHBG decreased slightly,
most probably due to the anti-oestrogenic effect of LNG
on EE.
As the ovarian activity increases during a pill-free
interval, this leads to a raised androgen synthesis which is
only reduced after several days of a continuous pill intake
[16]. Therefore, in the present study no decrease could be
observed (in the current trial blood samples were taken
during days 1–8). In another clinical trial in which EE/
CMA (Belara) was compared to EE/desogestrel (Grünen-
thal, data on file) and blood samples were collected on
later days of the cycle (days 18–21), a more pronounced
suppression of androgen levels could be seen.
Additionally, it has to be mentioned that both pill
starters and pill switchers were allowed to enter the study
so that the baseline values had most probably already
been influenced by the previous intake of another oral
contraceptive.
Despite the minimal observed changes in the androgen
levels over the course of the study, the clinical signs of
androgenization decreased strikingly under EE/CMA.
Thus, Belara can be recommended as a treatment for
women with mild to moderate clinical signs of acne and/
or other androgen-related disorders and the wish for effi-
cient and safe contraception.
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